Abstracts Archive - Page 38 of 2607 - ACR Meeting Abstracts

Abstract Number: 0276 • ACR Convergence 2025
Plasma Proteomic Profiling Identifies Inflammatory Proteins and Pathways Associated With Non-idiopathic and Idiopathic Retroperitoneal Fibrosis
Thomas Pelowitz, Benjamin Hur, Kenneth Warrington, Jaeyun Sung and Matthew Koster, Mayo Clinic, Rochester, MN
Background/Purpose: Retroperitoneal fibrosis (RPF) is a rare fibroinflammatory disease of the retroperitoneum that can lead to obstructive uropathy and other life-threatening complications. While RPF can…
Abstract Number: 0346 • ACR Convergence 2025
Fibroblast Growth Factor-23 and Bone Status in Patients with Chronic Kidney Disease Compared to a Healthy Control Group and Its Relationship with Cardiovascular Risk
José Rodríguez gago¹, Carolina Tornero², Lina León³, María Luisa González-Casaus³, Luisa Fernanda Giraldo³, Gloria del Peso³, Diego Garrido³, Teresa López³, Mónica Coronado³, María Auxiliadora Bajo⁴, Sara García³, María Gema Serrano³, Marta Ossorio³, Alejandro Balsa³ and Pilar Aguado³, ¹Hospital Universitario La Paz, MADRID, ²Hospital La Paz, Madrid, Spain, ³Hospital Universitario La Paz, Madrid, Spain, ⁴Hospital Universitario de la Princesa - ISS Princesa, Madrid, Spain
Background/Purpose: Chronic kidney disease (CKD) is linked to increased vascular comorbidity and fracture risk. This study aims to assess bone status in CKD patients versus…
Abstract Number: 0333 • ACR Convergence 2025
Diagnostic Test Accuracy of Artificial Intelligence in Early Diagnosis of Osteoarthritis: A Systematic Review and Meta-Analysis of 45,588 Knees
Mohamed Abdelsalam¹, Hadeer Hafez², Omar Sameh Nabil El Sedafy¹, Nourhan Abouelella³, Ahmed Abdulhafeez Hamza³, Omnia Samy El-Sayed⁴, Mohamed Reda Awad⁵, Gihan Omar³ and Hazem E. Mohammed⁶, ¹Misr University For Science and Technology, ⁶ october, Al Jizah, Egypt, ²⁶th October University, ⁶ october, Al Jizah, Egypt, ³Faculty of Medicine, Misr University for Science and Technology, ⁶ october, Al Jizah, Egypt, ⁴Misr University For Science and Technology, Nasr City, Al Qahirah, Egypt, ⁵Al Azhar University, Cairo, Egypt, Giza, Al Jizah, Egypt, ⁶Faculty of Medicine, Assiut university, Assiut, Egypt, assyut, Asyut, Egypt
Background/Purpose: Artificial intelligence (AI) rapid advancement opens new opportunities in the field of rheumatology. With better imaging, AI may help find early osteoarthritic changes that…
Abstract Number: 0296 • ACR Convergence 2025
Aggregation of HARS1 and internalized antibodies in muscle biopsies of patients with antisynthetase syndrome and anti-Jo1(HARS) autoantibodies
maria Casal-Dominguez¹, Iago Pinal Fernandez², Katherine Pak², Travis Kinder¹, Jon Musai¹, Ana Matas-Garcia³, Gloria Garrabou⁴, Iban aldecoa⁵, Albert Selva-O´callaghan⁶, José Milisenda⁷ and Andrew Mammen⁸, ¹National Institutes of Health, Bethesda, MD, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ³Muscle Research Unit, Internal Medicine Service, Hospital Clinic, Barcelona, Spain., Barcelona, Spain, ⁴Muscle Research Unit, Internal Medicine Service, Hospital Clinic, Barcelona, Spain., Barcelona, ⁵Pathology, Neurological Tissue Bank. Hospital Clinic of Barcelona-CDB-IDIBAPS/FCRB-University of Barcelona, Barcelona, Spain., Barcelona, ⁶Systemic Autoimmune Disease Section, Vall d'Hebron Institute of Research, Barcelona, Spain, Barcelona, ⁷Hospital Clinic de Barcelona, Barcelona, Spain, ⁸NIH, Bethesda, MD
Background/Purpose: Autoimmune inflammatory myopathies (IMs) comprise a diverse group of diseases that primarily affect the muscles and often involve the lungs, skin, and joints. Among…
Abstract Number: 0270 • ACR Convergence 2025
Diagnostic Challenge of IgG4-related Disease: Comparison Between ACR/EULAR, Umehara, and Okazaki Criteria
Rafael Gálvez Sánchez¹, Ivan Ferraz Amaro², Fernando Lopez Gutierrez³, Javier Loricera⁴, Pablo Martínez Calabuig⁵, Jorge Juan Fragío Gil⁶, Roxana González Mazarí⁷, Cristina Hormigos Martín⁸, DALIFER FREITES⁹, Maria Rodríguez Laguna⁸, Patricia Moya Alvarado¹⁰, Marta López I Gómez¹¹, Hector Corominas Macia¹⁰, Maite Silva Díaz¹², Guillermo González Arribas¹², Angel García Aparicio¹³, Judit Font-Urgelles¹⁴, Ivette Casafont Solé¹⁵, Elisabet Castaneda¹⁶, Carolina Merino Argumánez¹⁷, Raquel Zas Vaamonde¹⁸, Juan Molina Collada¹⁹, Sergio Rodríguez Montero²⁰, Rafael Melero Gonzalez²¹, Eva Galíndez Agirregoikoa²², Andrea Hernández²³, Lucia Pantoja Zarza²⁴, Ignacio Braña Abascal²⁵, Vega Jovaní²⁶, Elia Valls Pascual²⁷, Natalia Mena Vázquez²⁸, ADELA MARIA GALLEGO FLORES²⁹, Noelia Cabaleiro Raña³⁰, Raúl Veroz González³¹, Mariano Andrés³², Santos Castañeda Sainz³³ and Ricardo Blanco³⁴, ¹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ²Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ³Hospital Universitario Marqués de Valdecilla, Immunopathology Group -IDIVAL, Reumatología, Santander, Santander, Spain, ⁴Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ⁵Hospital General Universitario de Valencia, Spain/ Uversidad Catolica de Valencia San Vicente Martir, Valencia, Spain, Ontinyent, Spain, ⁶Hospital General Universitario, Valencia, Spain, ⁷Hospital General Universitario de Valencia, Reumatología, Valencia, Valencia, Spain, ⁸Hospital Clínico San Carlos, Reumatología, Madrid, Madrid, Spain, ⁹Rheumatology Service, San Carlos Clinical Hospital, Madrid, Madrid, Spain, ¹⁰Hospital de Sant Pau, Reumatología, Barcelona, Barcelona, Spain, ¹¹Hospital Universitario de Araba, Reumatología, Vitoria,, Vitoria, Spain, ¹²Complejo Hospitalario Universitario de A Coruña, Reumatología, A Coruña, Spain, ¹³Hospital Universitario de Toledo, Reumatología, Toledo, Toledo, Spain, ¹⁴Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ¹⁵Hospital German Trias i Pujol, Reumatología, Badalona, Badalona, Spain, ¹⁶Hospital Universitario Infanta Sofía, Reumatología, Madrid, Madrid, Spain, ¹⁷Hospital Universitario Puerta del Hierro, Reumatología, Madrid, Madrid, Spain, ¹⁸Hospital Universitario ¹² de Octubre, Reumatología, Madrid, Madrid, Spain, ¹⁹Hospital General Universitario Gregorio Marañón, Reumatología, Madrid, Madrid, Spain, ²⁰Hospital Universitario de Valme, Reumatología, Sevilla, Sevilla, Spain, ²¹Hospital Alvaro Cunqueiro, Reumatología, Vigo, Vigo, Spain, ²²BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, ²³Hospital Universitario de Gran Canaria Dr Negrin, Reumatología, Palmas de Gran Canaria, Gran Canaria, Spain, ²⁴Hospital General de Segovia, Reumatología, Segovia, Segovia, Spain, ²⁵Hospital Universitario Central de Asturias, Reumatología, Oviedo, Oviedo, Spain, ²⁶Hospital General Universitario de Alicante, Reumatología, Alicante, Alicante, Comunidad Valenciana, Spain, ²⁷Hospital General de Valencia, Reumatología, Valencia, Valencia, Spain, ²⁸Hospital Regional Universitario de Málaga, Reumatología, Málaga, Malaga, Spain, ²⁹Complejo Hospitalario don Benito Villanueva, Reumatología, Badajoz, Badajoz, Extremadura, Spain, ³⁰Hospital Universitario Montecelo, Reumatología, Pontevedra, Pontevedra, Spain, ³¹Hospital de Mérida, Reumatología, Mérida, Mérida, Spain, ³²Hospital General Universitario de Alicante, Reumatología, Alicante, Alicante, Spain, ³³Hospital Universitario La Princesa, Reumatología, Madrid Grupo de cooperación nacional de enfermedad relacionada con IgG⁴: Blanca García Magallón (Hospital Universitario Puerta del Hierro), Maite Odriozola Gil (Hospital Universitario de Valme), Cristina Arciniega (Hospital de Mérida), Maria Lourdes Mateo Soria (Hospital German Trias i Pujol), Santiago Muñoz (Hospital Universitario Infanta Sofía), Iñigo Jesús Rua Figueroa, (Hospital Universitario de Gran Canaria Dr Negrin), Sabela Fernández Aguado, (Hospital de Montecelo)., Madrid, Spain, ³⁴Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: IgG4-related disease (IgG4-RD) is a rare immune-mediated condition characterized by fibro-sclerosing inflammation, elevated serum and tissue IgG4 levels, and heterogeneous clinical manifestations. Several classification…
Abstract Number: 0001 • ACR Convergence 2025
ATG-201, a Novel Steric Hindrance-based Masking CD19xCD3 T-cell Engager (TCE) for the Treatment of B Cell-related Autoimmune Diseases
Gang Bian¹, Tengteng Li¹, Huiling Liu², Zaoshun Hu², Peng Chen¹, Jay Mei³ and Bing Hou³, ¹Shanghai Antengene Corporation Limited, Shanghai, China (People's Republic), ²Antengene (Hangzhou) Biologics, Hangzhou, Zhejiang, China (People's Republic), ³Antengene Corporation, Shanghai, China (People's Republic)
Background/Purpose: CD19-targeted therapies, such as chimeric antigen receptor (CAR)-T or T-cell engagers (TCE), have been approved for the treatment of B cell malignancies. By depleting…
Abstract Number: 0023 • ACR Convergence 2025
Longitudinal Proteomic Effects of Hydroxychloroquine in Individuals at Risk of Lupus: Differential Signatures in Progressors and Non-Progressors
Benjamin Jones¹, Miles Smith², Rufei Lu², Carla Guthridge², Susan Macwana², Wade DeJager³, Nancy Olsen⁴, Catriona Wagner⁵, Judith James², David Karp⁶ and Joel Guthridge², ¹Oklahoma State University, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma city, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, ⁴Penn State University/Milton S Hershey, Hershey, PA, ⁵Oklahoma Medical Research Foundation, Santa Cruz, CA, ⁶UT Southwestern Medical Center, Dallas, TX
Background/Purpose: Hydroxychloroquine (HCQ) is routinely prescribed for treatment of systemic lupus erythematosus (SLE) due to its efficacy at decreasing disease activity/SLE flares and strong benefit:risk…
Abstract Number: 0236 • ACR Convergence 2025
Safety and Efficacy of T Cell Engager Therapy in patients with refractory Autoimmune Disease
Laura Bucci¹, Sebastian Böltz¹, Melanie Hagen¹, Danae-Mona Nöthling¹, Tobias Rothe², Carlo Tur¹, Andreas Wirsching¹, Janina Auth³, jochen wacker¹, Markus Eckstein⁴, Stefano Alivernini⁵, Aline Bozec¹, Christina Bergmann¹, Maria Antonietta D'Agostino⁶, Maria Gabriella Raimondo¹, Georg Schett⁷ and Ricardo Grieshaber-Bouyer⁸, ¹Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ²Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlagen, Germany, ³Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Bayern, Germany, ⁴Institute of Pathology and Comprehensive Cancer Center EMN, Friedrich-Alexander- Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ⁵Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁶Division of Rheumatology and Clinical Immunology - Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁷Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ⁸University Hospital Erlangen, Erlangen, Germany
Background/Purpose: T cell engagers (TCEs) are a promising therapeutic strategy to treat autoimmune diseases (AID). However, long-term data remain limited.Methods: Patients with treatment-refractory AID were…
Abstract Number: 0377 • ACR Convergence 2025
New efforts to incorporate patient-reported outcomes into clinical trials for lupus therapeutics
Patti Katz¹, Anca Askanase², Nandan Baruah³, Wen-Hung Chen⁴, Nicole Cooper⁵, Anna Fisch³, Lili Garrard⁶, Meenakshi Jolly⁷, Veronica Vargas Lupo⁸, Carla Menezes⁹, Judith Mills³, Hoang Nguyen¹⁰, Teodora Staeva⁵, Josephine Park¹¹ and Zahi Touma¹², ¹UCSF, San Rafael, CA, ²Columbia University Medical Center, New York, NY, ³Lupus Voices Council, Lupus Accelerating Breakthroughs Consortium, New York, ⁴GlaxoSmithKline, Philadelphia, PA, ⁵Lupus Research Alliance, New York, ⁶FDA, CDER, SIlver Spring, MD, ⁷Rush University, Chicago, ⁸Lupus Voices Council, Lupus Research Alliance, New York, NY, ⁹Lupus Therapeutics, New York, NY, ¹⁰Lupus Research Alliance, New York, NY, ¹¹EMDSerono, Boston, MA, ¹²University of Toronto, Toronto, ON, Canada
Background/Purpose: Lupus Accelerating Breakthroughs Consortium (Lupus ABC) was formed by the Lupus Research Alliance as a public private partnership of people living with lupus, investigators,…
Abstract Number: 0383 • ACR Convergence 2025
Hidden Risk in Low Frailty: Impact of Elixhauser Comorbidities on In-Hospital Mortality Among Osteoporosis Patients — A Nationwide Analysis
Simran Bhimani¹, Anand Reddy Maligireddy², Sameer Bhimani³, Birju Bhatt⁴ and Nevena Barjaktarovic⁵, ¹The Wright Center for graduate medical education, Scranton, PA, ²The Wright Center GME, Scarnton, PA, ³The Wright Center for GME, scranton, PA, ⁴Solara Health NJ, New Jersey, NJ, ⁵The Wright Center, GME, Scranton, PA
Background/Purpose: Osteoporosis is a common condition associated with increased morbidity, particularly in older adults. While frailty is a known predictor of adverse outcomes, the independent…
Abstract Number: 0387 • ACR Convergence 2025
Association Between Juvenile Arthritis and Physical Activity Levels in U.S. Children: A Cross-Sectional Study Using the 2016–2021 National Survey of Children’s Health
William Soulsby¹ and Carolina Tamashiro², ¹University of California, San Francisco, San Francisco, CA, ²UCSF, San Francisco, CA
Background/Purpose: Juvenile arthritis (JA) is characterized by joint pain, stiffness, and decreased mobility, potentially affecting participation in physical activity (PA). Current guidelines from the CDC…
Abstract Number: 0330 • ACR Convergence 2025
Prevalence of Radiographic and Symptomatic Osteoarthritis, and Ultrasound Features at the Knee: The Johnston County Health Study
Maya Patel¹, Carolina Alvarez², Todd Schwartz³, Tessa Walker¹, Serena Savage-Guin¹, Jordan Renner¹, Jonathan Samuels⁴, Janice Lin⁵, Minna Kohler⁶, Catherine Bakewell⁷, Yvonne Golightly⁸ and Amanda Nelson¹, ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²University of North Carolina at Chapel Hill, Miami, FL, ³University of North Carolina-Chapel Hill, Chapel Hill, NC, ⁴NYU Langone, Rye Brook, NY, ⁵Stanford University, Palo Alto, CA, ⁶Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁷Intermountain Healthcare, Salt Lake City, UT, ⁸University of Nebraska Medical Center, Omaha, NE
Background/Purpose: To report sex and BMI differences among ultrasound (US) features of knee osteoarthritis (KOA), patient-reported symptoms (Ksx), radiographic KOA (rKOA), and symptomatic KOA (sxKOA),…
Abstract Number: 0304 • ACR Convergence 2025
Concordance for myositis-specific autoantibody detection between commercial enzyme-linked immunosorbent assay and line blot assay: a multi-center study across the Asia-Pacific region
Takahisa Gono¹, Vidya Limaye², Latika Gupta³, Vikas Agarwal⁴, Ho So⁵, JASMIN RAJA⁶, Warren Weng Seng Fong⁷, Suparaporn Wangkaew⁸, Andrea Low⁹, Akihiro Murakami¹⁰, Kimiko Hasegawa¹⁰, Takuya Isayama¹¹ and Masataka Kuwana¹, ¹Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ²Royal Adelaide Hospital, Adelaide, South Australia, Australia, ³School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham; Royal Wolverhampton NHS Trust; Centre for Musculoskeletal Research, School of Biological Sciences, The University of Manchester, Manchester; Francis Crick Institute, London, Birmingham, UK, United Kingdom, ⁴Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ⁵Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ⁶University Malaya, Subang Jaya, Malaysia, ⁷Singapore General Hospital, Singapore, ⁸Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand, ⁹Singapore General Hospital, Singapore, Singapore, ¹⁰Medical & Biological Laboratories co., ltd., Tokyo, ¹¹Medical & Biological Laboratories co., ltd., Tokyo, Japan
Background/Purpose: RNA/protein immunoprecipitation (IP) assays remain the “gold standard” for myositis-specific autoantibody (MSA) detection. However, the requirements for large-scale cell culture and radioisotopes limit its…
Abstract Number: 0345 • ACR Convergence 2025
Association Between Deprivation and Fracture Risk in a Regional UK Cohort
Hashem Cheema¹, Hamzah Amin² and marwan Bukhari³, ¹University Hospitals of Morecambe bay NHS foundation trust, Manchester, United Kingdom, ²Lancaster University, Lancaster, United Kingdom, ³University Hospitals of Morecambe bay NHS foundation trust, Lancaster, United Kingdom
Background/Purpose: Low socioeconomic status is associated with.an increase in osteoporosis and fracture risk respectively. A multitude of factors have been proposed including income, educational attainment…
Abstract Number: 0332 • ACR Convergence 2025
Safety, Short- and Long-Term Efficacy of Methotrexate in Osteoarthritis: A Systematic Review and Meta-Analysis
Mohamed Abdelsalam¹, Maryam Lasheen², Hadeer Hafez³, Bassant Elaraby Elsayed Badwy⁴, Omar Sameh Nabil El Sedafy¹ and Mohamed Reda Awad⁵, ¹Misr University For Science and Technology, ⁶ october, Al Jizah, Egypt, ²Misr University For Science and Technology, Helwan, Al Qahirah, Egypt, ³⁶th October University, ⁶ october, Al Jizah, Egypt, ⁴Misr University For Science and Technology, Nasr City, Al Qahirah, Egypt, ⁵Al Azhar University, Cairo, Egypt, Giza, Al Jizah, Egypt
Background/Purpose: Methotrexate (MTX), traditionally used for inflammatory conditions like rheumatoid arthritis, has well-established anti-inflammatory properties, recently gained interest as a potential therapeutic option for osteoarthritis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].